Grünwald, V., Keizman, D., Bedke, J., Staehler, M. D., Matveev, V. B., George, S., Hutson, T. E., Vaishampayan, U. N., Merchan, J. R., Eto, M., Rha, S. Y., Waddell, T., Sabbatini, R., Barthélémy, P., Burgents, J. E., Ren, M., Brown, I., Saal, H., Choueiri, T. K., Motzer, R. J. (2025). Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib + pembrolizumab (L+P) in the phase 3 CLEAR trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.531